Gewinn & Umsatz News zur WUXI BIOLOGICS Aktie

 

WuXi Biologics, one of China's largest contract drug developers, posted a 4.3 per cent increase in profit attributable to shareholders in the first half of the year, as stronger demand and improved capacity utilisation lifted revenue and margins. The Wuxi, Jiangsu-based company's net profit attributable to shareholders rose to 2.44 billion yuan (US$363 million) in the six months ended June, according to its filing to the Hong Kong stock exchange on Tuesday. Revenue increased 18.4 per cent to......

WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing. In a positive profit alert filed with the Hong Kong stock exchange on Wednesday, the company said profit attributable to equity shareholders would reach about 4.91 billion yuan (US$710 million), while revenue is set to climb 16.7 per cent to 21.79 billion yuan. Shares rose......